Condition
Advanced Mucosal Melanoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Not Yet Recruiting1
Unknown1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07155317Phase 2Recruiting
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
NCT06041724Phase 2Not Yet RecruitingPrimary
Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma
NCT03941795Phase 2UnknownPrimary
Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma
Showing all 3 trials